摘要
目前为止,胃癌依然是全球第五大恶性肿瘤,也是全球第二大癌症相关死亡原因。前期的研究发现,表皮生长因子受体2(HER2)阳性胃癌是一种特殊类型的胃癌,预后更差,这种胃癌在发生早期的上皮内瘤变组织中即存在HER2的高表达,且随着癌前病变去分化程度的升高,HER2的过表达率也显著增加,随着赫赛汀等靶向药物的出现HER2阳性胃癌的治疗问题出现了转机,但仅仅的赫赛汀治疗远远不够。HER2阳性胃癌的检查与治疗都还处于初级水平,近年来出现的液体活检技术以及多种治疗药物正在一步一步揭开HER2阳性胃癌神秘的面纱。其中液体活检技术不仅在效率上远超传统的免疫组化技术,而且可以实时动态监测曲妥珠单抗的疗效。本文综述了HER2阳性胃癌近阶段的研究进展,包括对于HER2阳性胃癌的治疗、耐药以及与免疫状态的关系,从而为临床实践提供一定的参考。
At present,gastric cancer is still the fifth largest malignant tumor in the world and the second largest cause of cancer-related death in the world.Previous studies have found that epidermal growth factor receptor 2(HER2)positive gastric cancer is a special type of gastric cancer with worse prognosis.This kind of gastric cancer has a high expression of HER2 in the early stage of intraepithelial neoplasia,and the overexpression of HER2 increases significantly with the increase of the degree of dedifferentiation of precancerous lesions.With the emergence of targeted drugs such as Herceptin,the treatment of HER2 positive gastric cancer has taken a turn for the better.But Herceptin alone is not enough.The examination and treatment of HER2 positive gastric cancer are still in the primary level.In recent years,liquid biopsy techniques and a variety of therapeutic drugs are unveiling the mystery of HER2 positive gastric cancer step by step.Among them,the liquid biopsy technique is not only much more efficient than the traditional immunohistochemical technique,but also can monitor the curative effect of Trastuzumab dynamically in real time.This paper reviews the recent research progress of HER2 positive gastric cancer,including the treatment of HER2 positive gastric cancer,drug resistance and the relationship with immune status,so as to provide some reference for clinical practice.
作者
孙克然
吕慧芳
王赛琪
陈小兵
SUN Keran;LYU Huifang;WANG Saiqi;CHEN Xiaobing(Department of Gastroenterology,Affiliated Tumor Hospital of Zhengzhou University,He′nan Province,Zhengzhou450000,China)
出处
《中国医药导报》
CAS
2020年第30期33-36,58,共5页
China Medical Herald
基金
国家自然科学基金资助项目(81472714)
河南省医学科技攻关计划项目(2018020486)。
